Tiziana Life Sciences PLC (TILST)

54.00
+1.00(+1.89%)
  • Volume:
    246,734
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    51.60 - 51.60

TILST Overview

Prev. Close
53
Day's Range
51.6-51.6
Revenue
-
Open
53
52 wk Range
46.44-195
EPS
-0.17
Volume
246,734
Market Cap
103.14M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
368,202
P/E Ratio
-
Beta
-1.34
1-Year Change
-67.76%
Shares Outstanding
194,612,289
Next Earnings Date
01 Dec 2021
What is your sentiment on Tiziana Life Sciences PLC?
or
Market is currently closed. Voting is open during market hours.

Tiziana Life Sciences PLC News

Tiziana Life Sciences PLC Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyNeutralStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyBuyStrong Sell

Tiziana Life Sciences PLC Company Profile

Tiziana Life Sciences PLC Company Profile

Employees
11

Tiziana Life Sciences plc, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology, inflammation, and infectious diseases. Its lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn’s, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. The company is also developing Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat COVID-19 patients. It has a collaboration agreement with FHI Clinical to conduct a Phase 2 clinical trials for treating hospitalized severe COVID-19 patients with intranasal foralumab. The company was incorporated in 1998 and is based in London, the United Kingdom.

Read More
  • thank god i sold out!
    0
    • Such strength in the US listing recently, momentum in price is starting in the UK folks...
      1
      • Its think its a prudent move buddy, I too am building a position here now.
        1
        • back in the game
          1
          • Its think its a prudent move buddy, I too am building a position here now.
            1
        • fingers crossed for the brazil results
          0
          • Sold all today, good luck to others still holding
            4
            • Ready for takeoff!
              0
              • Exited partially with big gains, will keep the other half for long term
                1
                • Trading Volume of 3x times of average suggest very positive momentum. FTSE 250 listing, very encouraging trial results and Dr Neil Graham from Regeneron Pharmaceuticals joining TILS are all very positive developments
                  1
                  • this has huge potential. looking positive for the Brazil trial in liason with Harvard University
                    2
                    • They will be moving up from Aim to ftse250 on 21.1.21... looks great for future...
                      1
                      • Wall Street is positive on Tiziana Life Sciences ADR Representing 2 Ord Shs (TLSA). On average, analysts give TLSA a Strong Buy rating. The average price target is $11, which means analysts expect the stock to climb by 488.24%
                        1
                        • Is it a good price to top up ? What do people think??
                          0
                          • Fantastic low price for new investors to get on board !! Get in while you can !! you would be insane not to at this bargain SP !!
                            0
                            • I am amazed that it was fallen that low, probably the rebound will be astonishingly fast when it comes and will catch the shortsellers off guard
                              0
                            • or it could fall further 🤔
                              0
                            • it will bounce fast but.....it will sink lower methinks
                              0
                          • Insider trading is a very positive sign for the things to come, can breach 200 mark soon if trials go as per predictions
                            1
                            • Ouch...!!!!!
                              0
                              • Yes that smarted somewhat
                                0
                              • Continues to smart
                                0
                            • 20% down?! looks like they lost the race to Pfizer!
                              0
                              • down 12% ? bit harsh!
                                0
                                • I’ve just been told by 212, that this share is suspended  The 212 staff Martin says “ I should not sell “ Please could someone confirm what’s going on  Just confused
                                  2
                                  • Get yourself a proper broker
                                    0
                                  • Tiziana plans plans a pinoff of its printstemER into another company called Accustem Life Sciences. This will be a demerger. Current shareholders will receive 1:1 share in the new company.
                                    0
                                  • because your broker is using ur shares for other trades. if u sell it means they have to sell out of their positions too. Conflict Of Interest, use an proper independent broker.
                                    0
                                • This is the reason why Tiziana Life Sciences are on the rise:Tiziana is proposing to spin off Accustem Sciences, which will own the StemPrintER and Spare Assets. The proposals were approved by shareholders at a general meeting held on 2nd October.The spin off is subject to a final court hearing to be held on the 27th October and if approved, will become effective on 2nd November. Shareholders are due to receive 1 Accustem Sciences share for each
                                  0
                                  • Today makes a big difference @ 193 Then 212 SELL @ 187 Big FAT Gap !!!!!!!!
                                    1
                                    • like i said on 3rd/aug, profit taking all the way from 235 to 125. Its now signalling reversal with buying pressue, TP295~325.
                                      1
                                      • Could get to 250 in next 4 weeks
                                        0
                                        • Really confused with this share, and trading 212 price DIFFERENCES
                                          1
                                          • is this company waiting for approvals or sales,or a nice rns update? any help would be nice
                                            1
                                            Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                            Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.